Kymera Therapeutics stock surges on early trial enrollment

By EC Assets · Published 25 June 2026

Kymera Therapeutics Inc. shares saw a significant increase in premarket trading. This surge followed the company's announcement of completing enrollment in its Phase 2b atopic dermatitis trial. The early completion has allowed Kymera to accelerate its expected topline data readout. Kymera's stock rose 8.8% in premarket trading Thursday. The company completed enrollment in its Phase 2b atopic dermatitis trial. This trial is known as BROADEN2 and evaluates KT-621. The earlier than anticipated